Healthcare / Drug Manufacturers - Specialty & GenericNasdaqGM
$2.82
-0.02 (-0.70%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-190000.00 · quality 48.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
41/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.1B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-0.9%
↓Gross Margin
42.8%
↓Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2017–2025 · 8 años de histórico normalizado
Revenue CAGR
+61.6%
FCF CAGR
—
FCF margin
-0.1%
FCF / Net income
0.02x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $146.6M · net income $-9.4M · FCF $-190000.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | $146.6M | $146.6M | $117.6M | $87.2M | $86.7M | $64.6M | $46.7M | $23.8M | $12.1M | $3.1M |
| Net Income | $-9.4M | $-9.4M | $41.1M | $-74.0M | $-168.7M | $-396.1M | $-73.1M | $1.17B | $-21.6M | $-1.5M |
| EBITDA | $-5.3M | $-5.3M | $-50.2M | $-71.8M | $-91.3M | $-276.6M | $-212.3M | $-149.0M | $-18.5M | $-5.4M |
| EPS | -0.02 | -0.02 | 0.11 | -0.19 | -0.45 | -1.07 | -0.21 | 3.33 | -0.12 | -0.01 |
| Gross Margin | 42.8% | 42.8% | 21.4% | 13.7% | 17.8% | -27.3% | -55.3% | -74.1% | 51.3% | 50.0% |
| Operating Margin | -13.3% | -13.3% | -50.6% | -91.6% | -120.3% | -452.2% | -469.6% | -645.5% | -168.7% | -194.5% |
| Net Margin | -6.4% | -6.4% | 34.9% | -84.8% | -194.5% | -613.5% | -156.5% | 4911.6% | -178.5% | -47.1% |
| Balance Sheet | ||||||||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
| Current Ratio | 21.87 | 21.87 | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||
| Free Cash Flow | $-190000.00 | $-190000.00 | $5.7M | $-46.3M | $-94.0M | $-164.8M | $-176.3M | $-169.9M | $-95.8M | $-37.2M |
| Returns | ||||||||||
| ROE | -0.9% | -0.9% | 3.9% | -6.7% | -14.8% | -29.6% | -4.3% | 66.7% | -14.6% | — |
| Valuation | ||||||||||
| P/E | — | — | 18.82 | — | — | — | — | — | — | — |
| P/B | 0.99 | 0.99 | 0.75 | 0.76 | 0.84 | — | — | — | — | — |
| Growth & Yield | ||||||||||
| Revenue Growth | 24.6% | 24.6% | 34.8% | 0.6% | — | 38.2% | 96.7% | 95.9% | 285.2% | — |
| EPS Growth | -118.2% | -118.2% | 157.9% | 57.8% | — | -409.5% | -106.3% | 2875.0% | -1100.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+42.4%
Start / end P/E
n/dx → n/dx
EPS bridge
0.11 → -0.02
Residual
+42.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.